Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor
Ahmed Mamai,Anh M. Chau,Brian J. Wilson,Iain D. Watson,Babu B. Joseph,Pandiaraju R. Subramanian, Monzur M. Morshed, Justin A. Morin, Michael A. Prakesh,Tianbao Lu,Pete Connolly,Douglas A. Kuntz,Neil C. Pomroy,Gennady Poda,Kong Nguyen,Richard Marcellus,Graig Strathdee,Brigitte Theriault,Ratheesh Subramaniam,Mohammed,Ayome Abibi,Manuel Chan,Jeffrey Winston,Taira Kiyota,Elijus Undzys,Ahmed Aman,Nigel Austin, Marc Du Jardin,Kathryn Packman, Ulrike Phillippar, Riccardo Attar,James Edwards,Jeff O'Meara,David E. Uehling,Rima Al-awar,Gilbert G. Prive,Methvin B. Isaac ACS MEDICINAL CHEMISTRY LETTERS（2023）
Key words
non-Hodgkin lymphoma (NHL),BCL6,protein-protein interaction,co-repressor,metabolic stability,oral bioavailability
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper